Next Article in Journal
Radiation Oncology: Times of Practice Change
Previous Article in Journal
Updated Recommendations from the Canadian National Consensus Meeting on HER2/neu Testing in Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 14
Issue 4
10.3747/co.2007.132
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

by
R. Buckstein
1,*,
R. M. Meyer
2,
L. Seymour
2,
J. Biagi
3,
H. MacKay
4,
S. Laurie
5 and
E. Eisenhauer
2
1
Division of Hematology, Odette Cancer Center, Toronto, ON, Canada
2
National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, ON, Canada
3
Cancer Centre of Southeastern Ontario, Kingston, ON, Canada
4
The Princess Margaret Hospital, Toronto, ON, Canada
5
Ottawa Regional Cancer Centre, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2007, 14(4), 154-161; https://doi.org/10.3747/co.2007.132
Submission received: 5 May 2007 / Revised: 5 June 2007 / Accepted: 5 July 2007 / Published: 1 August 2007

Abstract

Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (pdgfra) and beta (pdgfrb). Because angiogenesis is necessary for the growth and metastasis of solid tumours, and vegf is believed to have a pivotal role in that process, sunitinib treatment may have broad-spectrum clinical utility. In the present article, we discuss the biologic and clinical rationales that have recently led the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group to initiate four phase ii trials testing this agent in the following four different tumour types: relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Keywords: sunitinib; receptor tyrosine kinase inhibitor; ind; angiogenesis; ncic; phase II sunitinib; receptor tyrosine kinase inhibitor; ind; angiogenesis; ncic; phase II

Share and Cite

MDPI and ACS Style

Buckstein, R.; Meyer, R.M.; Seymour, L.; Biagi, J.; MacKay, H.; Laurie, S.; Eisenhauer, E. Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185. Curr. Oncol. 2007, 14, 154-161. https://doi.org/10.3747/co.2007.132

AMA Style

Buckstein R, Meyer RM, Seymour L, Biagi J, MacKay H, Laurie S, Eisenhauer E. Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185. Current Oncology. 2007; 14(4):154-161. https://doi.org/10.3747/co.2007.132

Chicago/Turabian Style

Buckstein, R., R. M. Meyer, L. Seymour, J. Biagi, H. MacKay, S. Laurie, and E. Eisenhauer. 2007. "Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185" Current Oncology 14, no. 4: 154-161. https://doi.org/10.3747/co.2007.132

APA Style

Buckstein, R., Meyer, R. M., Seymour, L., Biagi, J., MacKay, H., Laurie, S., & Eisenhauer, E. (2007). Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185. Current Oncology, 14(4), 154-161. https://doi.org/10.3747/co.2007.132

Article Metrics

Back to TopTop